Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

When a patient with obesity reports a new symptom, many physicians are quick to focus on the excess weight without exploring alternative reasons. Wrong approach, experts said.

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

A clinical practice guideline that stresses a multidisciplinary approach is intended to help clinicians manage obesity in ...